EMEA-002472-PIP03-22 - paediatric investigation plan

Beremagene geperpavec

Key facts

• Active Substance:
  Beremagene geperpavec
• Therapeutic area:
  Dermatology
• Decision number:
  P/0464/2022
• PIP number:
  EMEA-002472-PIP03-22
• Pharmaceutical form(s):
  Gel
• Condition(s) / indication(s):
  Treatment of dystrophic epidermolysis bullosa
• Route(s) of administration:
  Topical use
• Contact for public enquiries:

  Krystal Biotech, Inc.

  email: [e-mail]; tel: [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  28/10/2022

Decision

P/0464/2022 : EMA decision of 28 October 2022 on the agreement of a paediatric investigation plan for beremagene geperpavec (EMEA-002472-PIP03- 22)

Reference Number: EMA/790731/2022